Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia, Chaillon et al., 2021, Addiction.

Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care, Vallecillo et al., 2022, Drug and Alcohol Dependence Reports.

Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients’ and prescribers’ experiences with changes in unsupervised dosing, Corace et al., 2022, International Journal of Drug Policy.

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients, Moss et al., 2022, PLOS One Collection Social Psychiatry.

Prevalence of Respiratory Disorders during Sleep among Subjects of Methadone Maintenance Therapy Program, Talaei et al., 2021, Addiction & Health.

Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial, Skulberg et al., 2022, Addiction.

Golden opportunity for intervention? Identifying vitamin D deficiency in patients with substance use disorders in hospital, Smith et al., 2022, BMJ Open Quality.

Meeting people where they are: implementing hospital-based substance use harm reduction, Perera et al., 2022, Harm Reduction Journal.

Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse, Tay et al., 2022, Substance Abuse and Rehabilitation.

Inhalative Suchtmittel – eine Herausforderung für die Lunge, Kemény et al., 2022, Pneumologe.

Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations, Welsh et al., 2022, International Journal of Drug Policy.

Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine TrialsA Systematic Review and Meta-analysis, Haas et al., 2022, JAMA Network.

No party, no drugs? Use of stimulants, dissociative drugs, and GHB/GBL during the early COVID-19 pandemic, Bendau et al., 2022, International Journal of Drug Policy.

Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories, Richards et al., 2022, British Journal of Pain.

Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials, Thomas et al., 2021, Addiction.

Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model, Alexander et al., 2021, Addiction.

The Association between Chronic Heroin Smoking and Chronic Obstructive Pulmonary Disease, Bitar et al., 2021, Journal of Pharmay and Bioallied Sciences.

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder, Chawar et al., 2021, Addiction Science and Clinical Practice.

Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada, Kurz et al., 2021, Journal of Substance Abuse Treatment.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence, Farrell et al., 2022, International Journal of Drug Policy.

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report, Menard et al., 2021, The Mental Health Clinician.

Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives, Aronowitz et al., 2021, Harm Reduction Journal.

Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018, Pierce et al., 2021, European Psychiatry.

Opioid free anesthesia: evidence for short and long-term outcome, Bugada et al., 2021, Minerva Anestiologica.

Optimizing Treatment for Opioid Use Disorder, Brady, 2021, The American Journal of Psychiatry.

The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy, Cheetham et al., 2021, Dovepress.

Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials, Smart et al., 2021, Addiction.

Addiction as a brain disease revised: why it still matters, and the need for consilience, Heilig et al., 2021, Neurophsychopharmacology.

Emerging socio-economic disparities in COVID-19-related deaths during the second pandemic wave in Germany, Hoebel et al., 2021, International Journal of Infectious Diseases.

Substance use disorder and the baby boom generation: Does Berlin outpatient addiction care face a sustained change? Specht et al., 2021, Drug and Alcohol.

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study, Koeck et al., 2021, Frontiers in Psychiatry.

Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey, Evens et al., 2021, Frontiers in Psychiatry.

Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs, Durand et al., 2021, Journal of Clinical Medicine.

Estimating the number of children in households with substance use disorders in Germany, Kraus et al., 2021, Child and Adolescent Psychiatry and Mental Health.

Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT), Mahu et al., 2021, Drug and Alcohol Dependence.

Motives for opioid use explain the relation between borderline personality disorder pathology and opioid use problems, Scamaldo et al., 2021, Psychiatry Research.

Loneliness, Mental Health, and Substance Use among US Young Adults during COVID-19, Horigian et al., 2021, Journal of Psychoactive Drugs.

Investigating Mental Health Implications for Drug Court Participants, Humenik et al., 2020, International Journal of Offender Therapy and Comparative Criminology.

Mental health and substance use affect perioperative opioid demand in upper extremity trauma surgery, Cunningham et al., 2021, Journal of Shoulder and Elbow Surgery.

Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year, Bart et al., 2021, Journal of Substance Abuse Treatment.

Use of Medication-Assisted Treatment in Emergency Departments, Substance Abuse and Mental Health Services Administration (SAMHSA).

Substance abuse and cancer, Moussas et al., 2017, Psychiatriki.

Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19, Brothers et al., 2021, Journal of Substance Abuse Treatment.

Closing the brain–heart loop: Towards more holistic models of addiction and addiction recovery, Eddie et al., 2020, Addiction Biology.

Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort, Crowell et al., 2021, AIDS Research and Therapy.

Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment, Huang et al., 2021, Frontiers in Endocrinology.

A Systematic Review of Opioid Use Disorder and Related Biomarkers, Bryant et al., 2021, Frontiers in Psychiatry.

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting – a case series, Soyka et al., 2021, The American Journal of Drug and Alcohol Abuse.

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience, Sandmann et al., 2021, Open Forum Infection Diseases.

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis, Santro et al., 2021, JAMA Psychiatry.

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department, Hawk et al., 2021, Annals of Emergency Medicine.

Sense of coherence, social support and religiosity as resources for medical personnel during the COVID-19 pandemic: A web-based survey among 4324 health care workers within the German Network University Medicine, Schmuck et al., 2021, PLOS ONE.

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review, Soyka, 2021, Frontiers in Pharmacology.

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, Sarris et al., 2020, BMC Psychiatry.

Risk Factors for Opioid-Use Disorder and Overdose, Webster, 2017, Anesthesia & Analgesia.

Management and monitoring of opioid use in pregnancy, 2020, Rausgaard et al., Acta Obstetricia et Gynecologica Scandinavica.

Detachment, peer pressure, and age of first substance use as gateways to later substance use, Gallegos et al., 2021, Drug and Alcohol Dependence.

Rohypnol-induced sexual dysfunction is via suppression of hypothalamic-pituitary-testicular axis: An experimental study in rats, Oluwole et al., 2021, Andrologia.

Advances in the science and treatment of alcohol use disorder, Witkiewitz et al., 2019, Science Advances.

The Psychonauts’ Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity, Catalani et al., 2021, Pharmaceuticals.

Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder, Meyer et al., 2021, Frontiers in Psychiatry.

Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial, Ray et al., 2021, The American Journal of Psychiatry.

The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? Tracy et al., 2021, Journal of Substance Abuse Treatment.

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review, Adams et al., 2021, Addiction Science & Clinical Practice.

Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance, Ershad et al., 2020, Journal of Addiction Medicine.

Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk? Au et al., 2021, Harm Reduction Journal.

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department, Hawk et al., 2021, Annals of Emergency Medicine.

Mobile methadone dispensing in Delhi, India: implementation research, Rao et al., 2021, Bulletin of the World Health Organization.

The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases, Stöver et al., 2021, Harm Reduction Journal.

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy, Schmidbauer et al., 2021, PLOS One.

The epidemic of fentanyl misuse and overdoses: challenges and strategies, Volkow, 2021, World Psychiatry.

Opioid-Induced Tolerance and Hyperalgesia, Mercadante et al., 2019, CNS Drugs.

Opioid utility function: methods and implications, Jan van Dam et al., 2020, Annals of Palliative Medicine.

Opioid Therapy in Acute and Chronic Pain, Nafziger et al., 2018, The Journal of Clinical Pharmacology.

When less is more: Opioid use in the emergency department, Patanwala, 2019, American Journal of Health-System Pharmacy.

Buprenorphine Treatment for Opioid Use Disorder: An Overview, Shulman et al., 2019, CNS Drugs.

Estimation of the Social Costs of Illegal Drug Use in Poland Using Standardized Methodology, Mielecka-Kubie, 2020, The Journal of Mental Health Policy and Economics.

Use of cognitive enhancers: methylphenidate and analogs, Carlier et al., 2019, European Review for Medical and Pharmaceutical Sciences.

Reprint of: Biotechnologies and the future of opioid addiction treatments, Wolfe et al., 2021, International Journal of Drug Policy.

Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients, Guillery et al., 2021, European Addiction Research.

Injecting drug use, the skin and vasculature, Robertson et al., 2020, Addiction.

Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey, Radfar et al., 2021, Frontiers in Psychiatry.

The Role of Risk or Contributory Death Factors in Methadone-Related Fatalities: A Review and Pooled Analysis, Giorgetti et al., 2021, Metabolites.

Methadone overdose in patients following methadone mainte-nance treatment:A three years overview in the district of Bari (South-Italy), Favia et al., 2021, Clinica Terapeutica.

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report, Palis et al., 2021, Harm Reducation Journal.

Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries, Fonseca et al., 2021, Frontiers in Psychiatry.

Do gabapentin or pregabalin directly modulate the µ receptor?, Manandhar et al., 2021, Peer J.

International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder, Özgen et al., 2020, European Addiction Research.

Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany, Scherbaum et al., 2021, Frontiers in Psychiatry.

Drug-related deaths and mortality in EuropeUpdate from the EMCDDA expert network, European Monitoring Centre for Drugs and Drug Addiction, 2021.

Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway, Chalabianloo et al., 2021, Substance Abuse Treatment, Prevention, and Policy.

Gender Differences on Methadone Maintenance Treatment Outcome among Patients with Opioid use Disorder: A Systematic Review, Rizal et al., 2020, Journal of Pharmacy & BioAllied Sciences.

New Approaches in Drug Dependence: Opioids, Mielau et al., 2021, Current Addiction Reports.

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients, Delorme et al., 2021, Frontiers in Psychiatry.

Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes, Oliveira et al., 2021, Acta médica portuguesa.

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis, Santo et al., 2021, JAMA Psychiatry.

Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment, Khatri et al., 2020, Journal of Substance Abuse Treatment.

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies, Fava et al., 2020, Molecular Psychiatry.

Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine, Lehmann el al., 2021, Journal of Substance Abuse Treatment.

Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes, Gnanapandithan el al., 2021, Clinics and Practice.

Behandlung opioidabhängiger Inhaftierter – Einstellungen und Behandlungspraxis des medizinischen Personals in bayerischen Justizvollzugsanstalten, Weiss et al., 2021, Gesundheitswesen.

Empfehlungen zur substitutionsgestützten Behandlung bei Minderjährigen, Erbas et al., 2021, Bayerische Akademie für Sucht- und Gesundheitsfragen.

Factors Associated with Low Bone Density in Opioid Substitution Therapy Patients: A Systematic Review, Ramli et al., 2021, International Journal of Medical Sciences.

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine, Lintzeris et al., 2021, JAMA Network Open.

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors, Beard et al., 2021, Addiction.

Folgen der COVID-19-Pandemie für Menschen mit Schizophrenie, Demenz und Abhängigkeitserkrankungen, Adorjan et al., 2021, Nervenarzt.

COVID‐19 Vaccination among socially vulnerable people who use drugs, Arcadepani et al., 2021, Addiction.

Addiction as a brain disease revised: why it still matters, and the need for consilience, Heilig et al., 2021, Neuropsychopharmacology.

Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis, Stone et al., 2021, Lancet Psychiatry.

Prolonged-release buprenorphine formulations: Perspectives for clinical practice, Chappuy et al., 2020, Therapie.

Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis, Link et al., 2020, American Journal of Obstetrics & Gynecology.

The dopamine theory of addiction: 40 years of highs and lows, Nutt et al., 2015, Nature Reviews Neuroscience.

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone, Rolland et al., 2021, Drug and Alcohol Dependence.

Abuse‐deterrent extended‐release oxycodone and risk of opioid‐related harm, Paljarvi et al., 2021, Addiction.

Tapentadol:An Opioid of Abuse Acquired Online, Ansley et al., 2020, The Primary Care Companion for CNS Disorders

Mindfulness meditation improves emotion regulation and reduces drug abuse, Tang et al., 2016, Drug and Alcohol Dependence.

Ibogaine and addiction in the animal model, a systematic review and meta-analysis, Belgers et al., 2016, Translational Psychiatry.

Historical Review: Opiate Addiction and Opioid Receptors, Wang, 2018, Cell Transplantation.

Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking, Lepack et al., 2020, Science.

Impact of Continuing Care on Recovery From Substance Use Disorder, McKay, 2021, Alcohol research.

Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency, Wenzel et al., 2021, Journal of Substance Abuse Treatment.

Filling the Gaps: Planning for the Disaster Health Needs of Patients Taking Opioids and People Using Illicit Drugs

Estimated televised alcohol advertising exposure in the past year and associations with past 30-day drinking behavior among American adults: results from a secondary analysis of large-scale advertising and survey data, Niederdeppe et al., 2021, Addiction.

Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use, Magidson et al., 2021, Journal of Substance Abuse Treatment.

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada, Morin et al., 2020, The International Journal on Drug Policy.

Creating an ethical culture to support recovery from substance use disorders, Williamson, 2020, Journal of Medical Ethics.

When Physical and Social Pain Coexist: Insights Into Opioid Therapy

Is substance use changing because of the COVID‐19 pandemic? Conceptual and methodological considerations to delineating the impact of the Covid‐19 pandemic on substance use and abuse

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE), Schulte et al., 2020, Frontiers in Psychiatry.

Forty-eight years of research on psychosocial interventions in the treatment of opioid use disorder: A scoping review, Wild et al., 2021, Drug and Alcohol Dependence.